Managing pain: An exploration of psychotropic medications

Positive topline results from a pair of identical phase 3 trials support the submission of a supplemental New Drug Application to the FDA for Arcutis Biotherapeutics’ roflumilast cream 0.15%, a once-daily topical to treat mild to moderate atopic dermatitis (AD) in children 6 years or older.

Contemporary Pediatrics sits down exclusively with Sheila Fallon Friedlander, MD, a professor dermatology and pediatrics, to discuss the one key condition for which she believes community pediatricians should be especially aware-hemangiomas.

Hair loss is a condition that is often distressing and difficult to treat, particularly in adolescents. Here’s what you should know.

In this Contemporary Pediatrics interview, Bernard A. Cohen, MD, discusses VP-102, approved by the FDA on July 22, 2023, to treat molluscum contagiosum in pediatric patients 2 years and up.

The fully online training program, the MOPD Foundations of Pediatric Dermatology Certificate Course, was created by the founders of the Masters of Pediatric Dermatology (MOPD) Symposium and includes lectures, presentations, and downloadable resources for clinicians.

Following the resubmission of a new drug application, the FDA has approved VP-102 to treat molluscum contagiosum, a contagious skin disease transmitted through direct skin-to-skin contact that primarily affects children.